| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 4,152,642 | 4,660,301 | ||
| General and administrative | 648,507 | 883,727 | ||
| Total operating expenses | 4,801,149 | 5,544,028 | ||
| Loss from operations | -4,801,149 | -5,544,028 | ||
| Loss before income taxes | -4,801,149 | -5,544,028 | ||
| Income taxes provision | - | 850 | ||
| Net loss | -4,801,149 | -5,544,878 | ||
| Net loss applicable to common stock per share, basic (in dollars per share) | -0.13 | -0.15 | ||
| Net loss applicable to common stock per share, diluted (in dollars per share) | -0.13 | -0.15 | ||
| Weighted average common stock outstanding, basic (in shares) | 37,096,024 | 36,165,589 | ||
| Weighted average common stock outstanding, diluted (in shares) | 37,096,024 | 36,165,589 | ||
Estrella Immunopharma, Inc. (ESLAW)
Estrella Immunopharma, Inc. (ESLAW)